Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

O'Donnell PH et al. - Data does not exist with adjuvant therapy in bladder cancer, and adjuvant therapy for upper tract disease is further complicated by the difficulty of administering cisplatin-based regimens to patients who may suffer a decrement in renal function following nephrectomy. Therefore, until and unless specific trials are conducted, the most reasonable standard for locally advanced upper tract urothelial cancer is neoadjuvant, cisplatin-based combination chemotherapy prior to nephrectomy and surgical resection.

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address